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Two simple, accurate, and sensitive methods were developed for the determination of netobimin in the presence of its degradation
product.Method(A)wasanHPLCmethod,performedonC18columnusingacetonitrile/methanol/0.01Mpotassiumdihydrogen
phosphate (56:14:30 by volume) as a mobile phase with a ﬂow rate of 0.5mL/min. Detection was performed at 254nm. Method
(B) was a TLC method, using silica gel 60 F254 plates; the optimized mobile phase was toluene/methanol/chloroform/ammonium
hydroxide (5:4:6:0.1 by volume). The spots were scanned densitometrically at 346nm. Linearity ranges were 1–10μg/mL for
method (A) and 0.5–5μg/band for method (B), and the mean percentage recoveries were 99.3±0.7% and 99.7±0.7% for methods
(A) and (B), respectively. The proposed methods were found to be speciﬁc for netobimin in the presence of up to 90% of its
degradation product. Statistical comparison between the results obtained by these methods and the manufacturer method was
done, and no signiﬁcance diﬀerence was obtained.
1.Introduction
Netobimin, 2-{3-meth-oxycarbonyl-2-[2-nitro-5-(propylthi-
o)phenyl]guanidi-one} ethanesulphonic acid, is an anthel-
mintic drug used in veterinary medicine, Scheme 1 [1]. It
is a probenzimidazole with primary antinematodal activity
at a dosage of 7.5mg/kg, and at elevated dosages (15 and
20mg/kg) it is eﬀective against adult stages of ﬂukes includ-
ingDicrocoeliumdendriticum(92–98.9%eﬃcacy)andF. hep-
atica (90.7% eﬃcacy) [2]. Netobimin and its metabolites al-
bendazole and albendazole oxide were all of low acute toxi-
city when given by oral route or parenteral routes. No
deaths were caused with oral doses of up to 6900mg/Kg
body weight in mice, 5000mg/Kg body weight in rats, and
2000mg/Kg body weight in dogs. Intravenous LD50 values
were 344 and 570mg/Kg body weight in male and female
mice, respectively, and 786 and 659mg/Kg body weight in
male and female rats, respectively [3].
Netobimin is not oﬃcial in any pharmacopoeia; hence
no oﬃcial method is available for its estimation. Literature
survey reveals diﬀerent methods for the determination of
netobimin in biological samples. Gokbulut et al. [4, 5]d e -
veloped a method for the determination of netobimin in
plasma, blood, and faecal excretions and its respective meta-
bolites by high-performanceliquid chromatography (HPLC)
using a chiral phase-based HPLC following oral administra-
tion. Dowling et al. [6] developed an LC method with UV
detection at 298nm for the determination of netobimin in
bovine liver. However, there are no reported methods for
the determination of the drug in its pure powdered form or
stability-indicating methods. This paper presents a study of
alkaline degradation of netobimin, followed by the develop-
ment of two chromatographic stability-indicating methods
for the determination of the drug in its pure powder and in
suspension forms.
TheproposedHPLCandTLCdensitometricmethodsare
sensitive, fast, and stability indicating, used for simultaneous
determination of netobimin in the presence of its degrada-
tion product. HPLC has the advantages of its discriminating2 Journal of Analytical Methods in Chemistry
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Scheme 1: The degradation pathway of netobimin.
power to resolve the drug from its degradation product and
its ability to operate at ambient temperature that would
not contribute to the degradation of the drug. TLC has be-
come a routine analytical technique due to the possibility of
applicationofseveralsamplestoberunsimultaneouslyusing
a small amount of mobile phase, thus lowering the time and
cost per analysis.
2. Experimental
2.1. Instruments. An Agilent HPLC instrument was obtained
from Aligant (Waldbronn, Germany), and densitometer-
dual wave length ﬂying spot was obtained from Shimadzu
(Tokyo, Japan), UV lamp with short wave length 254nm
was obtained from Desaga (Waldbronn, Germany), and thin
layer chromatographic plates precoated with silica gel 60 F254
10 × 20cm were obtained from Fluka (Switzerland, Ger-
many).TheIRspectrophotometerwasobtainedfromBruker
Optics (Ettlingen, Germany). Mass spectrophotometer was
obtained from Agilent Technologies, Wilmington, DE.
(Hewlett Packard Model 5988A GC/MS, fragmentation pat-
terns arise from electron impact ionization.
2.2. Reagents. Methanol and acetonitrile HPLC grade were
obtained from SD Fine-Chem Limited (Mumbai, India).
Sodium hydroxide, hydrochloric acid, toluene, chloroform,
methanol, ammonium hydroxide, and potassium dihydro-
gen phosphate were obtained from ADWIC (Cairo, Egypt).
2.3. Samples
2.3.1. Reference Sample. Netobimin-pure sample was kindly
supplied by Shering-Plough Sante Animale La Grindoliere
49500 Serge, France B.N. 21787, its purity was found to be
99.9 ±0.5% according to the manufacturer method [7].
2.3.2.PharmaceuticalFormulation. Hapadexoralsuspension
5% was supplied by Shering-Plough Animale La Grindoliere
49500 Serge, France, B.N. 8389, each 1mL is claimed to con-
tain 50mg of netobimin.
2.3.3. Degraded Sample. T h ed e g r a d a t i o np r o c e s s e su n d e r
acid, alkaline, oxidative, and thermal conditions were fol-
lowed by TLC using three diﬀerent systems (toluene/meth-
anol/chloroform/ammonium hydroxide (5:4:6:0.1 by vol-
ume), methanol: 33% ammonium hydroxide (9:0.1v/v),
and ethyl acetate: methanol: 33% ammonium hydroxide
(8:1:0.2 by volume)), and the compound was found to
be degraded under alkaline conditions, yielding a single
component, as only one spot was obtained by TLC under the
three diﬀerent systems mentioned.
For the preparation of the alkaline degradation product,
netobimin(50mg)wasreﬂuxedwith50mL1MNaOHsolu-
tion for 5 hours and tested for complete degradation by TLC
using toluene/methanol/chloroform/ammonium hydroxide
(5:4:6:0.1 by volume) as the mobile phase. Only one spot
wasobservednotcorrespondingtonetobimin.Thedegraded
solution was then cooled and neutralized with 2M HCl till
pH was approximately 7. The solution was nearly evaporated
to dryness, cooled, and transferred quantitatively with
methanoltopreparesolutionofconcentration(equivalentto
0.5mg/mL of intact netobimin) in methanol.
2.4. Standard Solutions
2.4.1. Netobimin Stock Standard Solution. (0.5mg/mL) in
methanol.
2.4.2. Working Standard Solution. It is 0.05mg/mL in mobile
phase for method (A).
2.5. Degraded Solutions
2.5.1. Degradation Product Stock Solution. It is 0.5mg/mL in
methanol. Prepared as mentioned in Section 2.3.3.
2.5.2. Working Degradation Product Solution. It is 0.05mg/
mL in mobile phase for method (A).
2.6. Assessment of Selectivity/Speciﬁcity of the Methods. They
are laboratory-prepared mixtures containing diﬀerent ratios
of netobimin and its degradation product.
2.6.1. Method (A). Aliquots (0.9–0.1mL) of netobimin were
accurately transferred from its working standard solution
(0.05mg/mL) equivalent to 45–5μg. Aliquots (0.1–0.9mL)
of working degradation product solution (0.05mg/mL)
equivalent to 5–45μg were added, to prepare solutions of
concentration9–1μg/mLofnetobiminand1–9μg/mLofthe
degradation product in the mobile phase containing 10–90%
of the degradation product.Journal of Analytical Methods in Chemistry 3
2.6.2. Method (B). Aliquots (4.5–0.5mL) of stock standard
solution (0.5mg/mL) equivalent to 2.25–0.25mg were accu-
rately transferred, then aliquots (0.5–4.5mL) of degradation
product stock solution (0.5mg/mL) equivalent to 0.25–
2.25mg were added, to prepare solutions of concentration
450–50μg/mL of netobimin and 50–450μg/mL of the deg-
radationproductinmethanolcontaining10–90%ofthedeg-
radation product.
2.7. Procedures
2.7.1. Method (A)
(i) Linearity. Linearity was performed by preparing solu-
tions of concentrationrange 1–10μg/mL in the mobile phase
from the drug working standard solution (0.05mg/mL).
20μLofthepreviouslypreparedsolutionswasinjectedintri-
plicate using the following chromatographic conditions.
(a) Column: nucleosil, size 125 × 4mm, C18 5μm. The
column was equilibrated with the mobile phase until
steady baseline was obtained and column pressure
was stabilized.
(b) Mobilephase:Themobilephaseconsistedofacetoni-
trile:methanol:0.01M potassium dihydrogen phos-
phate in ratio of 56:14:30 by volume. The mobile
phase was ﬁltered using 0.45μm membrane ﬁlters
and degassed by ultrasonic vibrations for 30min.
(c) Temperature: the system was operated at ambient
temperature.
(d) Flow rate: the ﬂow rate was isocratic at 0.5mL/min.
(e) Detector wavelength: 254nm.
(f) Injection volume: 20μL.
The chromatogram was obtained, the average peak area ra-
tios obtained for each concentration of netobimin to that
of external standard 1μg/mL were plotted versus concentra-
tions, and the regression equation was computed.
(ii) Accuracy. The accuracy of the results was checked by
applyingthepreviouslymentionedprocedureunderlinearity
fordiﬀerentconcentrationsofpurenetobiminwithinthelin-
earity range. The concentrations of the drug were calculated
from the regression equation. The mean recovery percentage
and relative standard deviation were then calculated.
(iii) Precision
(a) Repeatability. Three concentrations of netobimin stock
standard solution (2, 4, and 6μg/mL) were analyzed three
times each, intraday, using the previously mentioned proce-
dure in Section 2.7.1(i). The mean recovery percentage and
relative standard deviation were then calculated.
(b) Intermediate Precision. The previously mentioned neto-
bimin samples were analyzed on three successive days
using the procedure stated under Section 2.7.1(i). The mean
recovery percentage and relative standard deviation were
then calculated.
(iv) Assessment of Selectivity/Speciﬁcity of the Method.
Twenty μL from the prepared mixtures was injected into the
liquid chromatograph. Then, the procedure was completed
as described in Section 2.7.1(i). The concentration of neto-
bimin was calculated by substitution in the corresponding
regression equation.
(v) Application of the Proposed Method for the Determina-
tion of Netobimin in Its Pharmaceutical Formulation. The
contents of the Hapadex oral suspension bottle were shack-
ed well, then 1mL equivalent to 50mg netobimin was quan-
titatively transferred into a beaker, and 50mL methanol was
added. The beaker was covered with watch glass and the
solution was stirred for 30 minutes using a magnetic stir-
rer, ﬁltered, the residue was washed three times each with
10mL methanol and ﬁltered, and the collected ﬁltrates were
accurately transferred to prepare a solution of approximately
0.5mg/mL in methanol. Suitable dilutions were made with
the mobile phase to prepare a solution of approximately
4μg/mL in the mobile phase. Then the procedure was
completed as described in Section 2.7.1(i). The concentra-
tion of netobimin was calculated by substitution in the cor-
responding regression equation.
(vi) System Suitability. The tailing factors, the resolution
factor, the selectivity factor, the theoretical plate count, and
the height equivalent to a theoretical plate (HETP) were
calculated.
2.7.2. Method (B)
(i) Linearity. Linearity was performed by preparing solu-
tions of concentration range 50–500μg/mL in methanol
from the stock standard solution (0.5mg/mL). Ten μL of the
prepared solutions, using 10μL Hamilton syringe, was ap-
plied as separate compact bands 20mm apart and 20mm
from the bottom of the plates. The chromatographic tank
was saturated with the mobile phase for one hour in as-
cending manner to a distance of 7cm from the spotting line
at room temperature and air-dried, and the plates were scan-
ned under the following conditions.
(a) Source of radiation: deuterium lamp.
(b) Photomode: reﬂection.
(c) Scan mode: zigzag.
(d) Result output: chromatogram and area under the
peak.
(e) Swing width: 10mm.
(f) Wavelength: 346nm.
The scanning proﬁle for netobimin was obtained. The
calibration curve relating the integrated peak area to the cor-
responding concentration was constructed, and the regres-
sion equation was computed.4 Journal of Analytical Methods in Chemistry
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Figure 1: IR spectrum of intact netobimin.
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Figure 2: IR spectrum of the degradation product of netobimin.
(ii) Accuracy. The accuracy of the results was checked by
applying the proposed method for the determination of dif-
ferent concentrations of pure netobimin within the lineari-
tyrange.Theconcentrationswerecalculatedfromtheregres-
sion equation. The mean recovery percentage and relative
standard deviation were then calculated.
(iii) Precision
(a) Repeatability. Three concentrations of netobimin stock
standardsolution(0.5,1,and2μg/band)wereanalyzedthree
times each, intraday, using the previously mentioned proce-
dure under Section 2.7.2(i). The mean recovery percentage
and relative standard deviation were then calculated.
(b) Intermediate Precision. The above-mentioned netobi-
minsampleswereanalyzedonthreesuccessivedaysusingthe
procedure stated in Section 2.7.2(i). The mean recovery per-
centage and relative standard deviation were then calculated.
(iv) AssessmentofSelectivity/SpeciﬁcityoftheMethod. Ten μL
of, the prepared mixtures was spotted on TLC plates and
theprocedurewascompletedasdescribedinSection 2.7.2(i).
The concentration of netobimin was calculated by substitu-
tion in the corresponding regression equation.
(v) Application of the Proposed Method for the Determination
of Netobimin in Its Pharmaceutical Formulation. Four mL
of the solution prepared (approximately 0.5mg/mL) as
described in Section 2.7.1(v) was accurately transferred to
prepare a solution of approximately 0.2mg/mL in metha-
nol. Then the procedure was completed as described in
Section 2.7.2(i). The concentration of netobimin was calcu-
lated by substitution in the corresponding regression equa-
tion.
3. Results and Discussion
The stability of netobimin was studied according to ICH
guidelines [8] for the following.
(a) Acid and alkaline stress: 0.1M HCl/0.1M NaOH for
16hrs, 0.2M HCl/0.2M NaOH for 16hrs, and 1M
HCl/1M NaOH for 4hrs and 5hrs.
(b) Oxidative condition: 3% H2O2 for 2hrs, 4hrs, 6hrs,
and 10hrs.
(c) Thermal degradation: at 100◦Ci na no v e nf o r2h r s ,
4hrs,and6hrs.
Since this work was concerned with the development of
stability-indicating methods for the determination of neto-
bimin, the degradation product was prepared in laboratory
as mentioned in Section 2.3.3. The structure of the isolated
alkaline degradation product was conﬁrmed using IR and
MS spectroscopy (Figures 1–4).
Figure 1 Shows the IR spectrum of the intact netobimin,
which is characterized by the absorption frequency of C=O
ester carbamate at 1769.37cm−1. On the other hand the IR
spectrum of the degradation product lacks the characteristic
carbamate C=O band and it shows an NH2 functionality at
3435.56, 2963.09cm−1 (Figure 2). This result is proved by
usingmassspectroscopy;theMSspectrumoftheintactneto-
bimin is characterized by the molecular ion m/z at 420 (M+.,
35.56%) (Figure 3). On the other hand, the MS spectrum of
the degradation product was characterized by the molecular
ion m/z at 362 (M+., 48.07%) (Figure 4).
This ﬁnding suggested the degradation pathway and
indicates that the degradation product of netobimin has the
structure illustrated in Scheme 1.
3.1. Method (A). HPLC has become the most versatile and
widespread technique used by the pharmaceutical industry
for quality control. It has many applications in the ﬁeld of
pharmaceuticals including the quantitative determination of
drugspresenteitheraloneorinpresenceoftheirdegradation
[9–12].
The proposed method is based on the diﬀerence in the
retention time between the intact drug and its degradation
product. The suitable mobile phase has been selected to
achieve the best separation of the drug from its degradation
product.Journal of Analytical Methods in Chemistry 5
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Figure 3: Mass spectrum of intact netobimin.
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Figure 4: Mass spectrum of the degradation product of netobimin.
Diﬀerentmobilephaseswithdiﬀerentratioswereinvesti-
gatedsuchas methanol:0.05M potassium dihydrogen phos-
phate (60:40v/v) and acetonitrile: 0.01M potassium dihy-
drogen phosphate (70:30v/v), but separation was not sat-
isfactory. By using acetonitrile:methanol:0.01M potassium
dihydrogen phosphate of 60:30:10 by volume, respectively,
and of 40:30:30 by volume, respectively, poor resolution
and tailed peaks were obtained, while upon adjusting the
ratioto56:14:30byv olume,respectiv ely ,satisfactorysepara
tionwasperformed,witharetentiontimeof1.834±0.03min
for netobimin and 3.449±0.03min for its degradation prod-
uct. This would permit quantitative determination of neto
bimin in presence of its alkaline-induced degradation prod-
uct (Figure 5).
Theaveragepeakarearatiosobtainedforeachconcentra-
tion of netobimin to that of external standard 1μg/mL were
plotted versus the corresponding concentration of the drug.
The proposed method was found to be valid in the range of
1–10μg/mL, and the regression equation was computed and
found to be
A = 0.9706C +0 .0365, r = 0.9998, (1)
where A is the peak area ratio, C is the concentration of the
drug in μg/mL, and r is the correlation coeﬃcient.
The proposed method was successfully applied for the
determination of the drug in pure powder form with mean
percentage recovery of 99.3 ± 0.7% (Table 1).
System suitability test according to the United States
Pharmacopoeia [13] was used to verify that the resolution
Table 1: Results of validation parameters of the responses and the
regression equations obtained by the proposed methods.
Parameters Method (A) Method (B)
Slopea 0.9706 0.1086
Intercepta 0.0365 0.0684
Correlation coeﬃcient 0.9998 0.9994
Concentration range 1–10μg/mL 0.5–5μg/band
Average accuracy (%) 99.3 99.7
S.D. 0.7 0.7
R.S.D.% 0.7 0.7
Speciﬁcity ± R.S.D. 99.4 ± 1.3 100.1 ± 1.2
Repeatabilityb% ±R.S.D. 100.1 ± 0.1 99.8 ± 0.6
Intermediate
precisionc% ±R.S.D. 99.8 ± 0.2 99.4 ± 0.2
aResults of ﬁve determinations.
bn = 3 ×3.
cn = 3 × 3.
and reproducibility of the chromatographic system were
adequate for the analysis to be done. Accordingly, system suit
ability was checked by calculating the column eﬃciency (N),
resolution (R), selectivity (α), and tailing factor (T), where
the system was found to be suitable (Table 2).
3.2. Method (B). Thin layer chromatography has become a
well-established technique for the assay of drugs either in
binary or in multicomponent mixtures [14, 15].6 Journal of Analytical Methods in Chemistry
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Figure 5: HPLC chromatogram of (a) the intact netobimin (7μg/mL) and (b) the degradation product (7μg/mL) using the speciﬁed
chromatographic conditions.
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Figure 6: Scanning proﬁle of TLC chromatogram of netobimin at
346nm.
The proposed method is based on the diﬀerence in the
Rf between the intact drug and its degradation product. The
suitable mobile phase has been selected to achieve the best
separation of the drug from its degradation product; other
necessary conditions have been established.
Diﬀerent solvent systems with diﬀerent ratios were tried
including chloroform:acetone (4:1v/v), where the drug
and the degradation product have not retained. By using
methanol:33% ammonium hydroxide (9:0.1v/v) separa-
tion of spots occurred but tailing was observed in the spot
of the degradation. The use of toluene:methanol:chloro-
form:33% ammonium hydroxide solution of 5:3:6:0.1 by
volumeresultedinpoorseparation,whileuponadjustingthe
Table 2: Parameters of system suitability test of method (A).
Parameter
Obtained value
Netobimin Degradation
product
Relative retention time (α) 1.88
Resolution (R) 11.61
Capacity factor (K) 1.22 3.18
Tailing factor (T) 0.8 0.86
Column eﬃciency (N) 4681 6551
HETP 0.0027cm/plate 0.0019cm/plate
ratioto5:4:6:0.1byvolumegoodseparationofnetobimin
and its degradation product was obtained. The instrumen-
tal conditions for densitometric measurement such as scan
mode and wavelength detection were optimized. The scan
mode chosen was zigzag mode, and the wavelength was
346nm. Netobimin was completely resolved from its degra-
dationproduct,anditsRf valuewas0.47.Ontheotherhand,
theRf valueofthedegradationproductwas0.74.Thiswould
permit quantitative determination of netobimin in presence
of its alkaline-induced degradation product (Figure 6).
A linear relationship between the concentration of neto-
bimin and the integrated peak area existed. The proposed
method was found to be valid in the range of 0.5–5μg/band,
and the regression equation was computed and found to be
A = 0.1086C +0 .0684, r = 0.9994, (2)
where A is the integrated peak area × 10−4, C is the con-
centration of the drug in μg/band, and r is the correlation
coeﬃcient.
The proposed method was successfully applied for the
determination of the drug in pure powder form with mean
percentage recovery of 99.7 ±0.7% (Table 1).
The speciﬁcity of the methods was proven by the analysis
of laboratory-prepared mixtures containing diﬀerent per-
centages of the degradation product. The proposed methods
were found to be speciﬁc for netobimin in presence of up to
90% of its degradation product (Table 3).Journal of Analytical Methods in Chemistry 7
Table 3: Results of analysis of netobimin in laboratory-prepared mixtures containing diﬀerent ratios of netobimin and its degradation
product in pure powder form by the proposed methods.
Method (A) Method (B)
Degradation% Concentration (μg/mL) Concentration (μg/band)
Netobimin Degradation product Recovery % Netobimin Degradation product Recovery %
10 9 1 100.8 4.5 0.5 98.1
20 8 2 98.2
30 7 3 100.4 3.5 1.5 100.7
40 6 4 98.2
50 5 5 100.8 2.5 2.5 100.9
60 4 6 98.2
70 3 7 98.7 1.5 3.5 100.2
80 2 8 98.6
90 1 9 100.8 0.5 4.5 100.5
Mean 99.4 100.1
S.D. 1.3 1.2
R.S.D. % 1.3 1.2
Table 4: Quantitative determination of netobimin in pharmaceutical formulation by the proposed methods and results of application of
standard addition technique.
Hapadex oral
suspension 5% B.N 8389
Method (A)
Found %a Claimed amount taken (μg/mL) Standard added (μg/mL) Recovery %b of added
100.3 4 2 99.4
98.9 4 4 99.0
101.2 4 6 99.1
Mean 100.1 99.2
S.D. 1.2 0.2
R.S.D. % 1.2 0.2
Hapadex oral
suspension 5% B.N 8389
Method (B)
Found %a Claimed amount taken (μg/band) Standard added (μg/band) Recovery %b of added
100.5 2 1 99.3
100.5 2 2 99.4
99.7 2 3 100.7
Mean 100.2 99.8
S.D. 0.5 0.8
R.S.D.% 0.5 0.8
aAverage of six determinations.
bAverage of six determinations.
The usefulness of the proposed methods for the analysis
of netobimin was studied by assaying Hapadex oral suspen-
sion 5% (Table 4). Samples were also spiked in order to asses
the validity of the proposed method (Table 4).
Results obtained by the proposed method for the deter-
mination of pure samples of the drug were statistically
compared to those obtained by the manufacturer method
of the drug [7], and no signiﬁcant diﬀerences were observed
(Table 5).
The accuracies were assessed by the determination of
pure netobimin samples within the linearity ranges; the
mean accuracies are given in (Table 1).
The repeatability and interday precision were evaluated
by assaying three freshly prepared solutions of the drug in
triplicate on the same day and on three successive days, res-
pectively, at concentrations within the linearity range for
both methods. RSD% shows the precision of the methods
(Table 1).
Validation of the proposed methods was made by mea-
suring range, accuracy, precision, repeatabilities, interday
precision, linearity, and speciﬁcity. Results obtained are de-
picted in Table 1. This data render the applicability of the
proposed method for the quality control of the drug formu-
lation.8 Journal of Analytical Methods in Chemistry
Table 5: Statistical analysis of the results obtained for the determi-
nation of netobimin in pure samples by the proposed methods and
those obtained by the manufacturer method.
Item Method
(A)
Method
(B)
Manufacturer’s
method ∗[7]
Mean 99.4 99.7 99.9
S.D. 0.7 0.7 0.5
R.S.D % 0.7 0.7 0.5
Variance 0.5 0.5 0.3
n 10 6 5
Students t 1.4 (2.160) 0.5 (2.262)
F test 1.7 (4.77) 1.7 (5.05)
Figures in parentheses are the corresponding tabulated values at P = 0.05.
∗[7] Manufacturer method HPLC, mobile phase methanol:0.05 M mono-
basic potassium phosphate of 60:40 by volume, respectively, UV set at
254nm.
The proposed HPLC and TLC methods are precise, ac-
curate, and sensitive. They can be used for the routine ana-
lysis of netobimin in pharmaceutical formulations and stabi-
lity-indicating methods. The ICH guidelines were followed
throughout the study for method validation.
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